A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 (Inhaled Sirolimus) for the Treatment of Pulmonary Hypertension
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Sirolimus (Primary)
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors OrphAI Therapeutics
Most Recent Events
- 13 Feb 2025 Planned End Date changed from 31 Dec 2025 to 30 Oct 2026.
- 13 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 30 Sep 2025.
- 02 Oct 2023 Planned End Date changed from 28 Feb 2025 to 31 Dec 2025.